The DDS2 capsule enables more precise dosing and higher local concentrations at the site of disease.
There remains a significant medical need for safe and effective therapeutics to treat ulcerative colitis and Crohn’s disease. Targeted drug delivery directly to the colon has the potential to improve drug absorption at the site of inflammation, improving the efficacy of treatment.
The Drug Delivery System 2 (DDS2) is an ingestible electronic capsule that can deliver therapeutic compounds to a defined location in the gastrointestinal tract. It is comprised of a drug reservoir containing a liquid formulation of the therapeutic compound, a removable cap, and an electronic module. We conducted this pre-clinical proof-of-concept study to demonstrate the functionality of the DDS2 capsule.1